These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2919868)

  • 1. Carbamazepine and its epoxide: relation of plasma levels to toxicity and seizure control.
    Theodore WH; Narang PK; Holmes MD; Reeves P; Nice FJ
    Ann Neurol; 1989 Feb; 25(2):194-6. PubMed ID: 2919868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbamazepine and its epoxide: an open study of efficacy and side effects after carbamazepine dose increment in refractory partial epilepsy.
    Semah F; Gimenez F; Longer E; Laplane D; Thuillier A; Baulac M
    Ther Drug Monit; 1994 Dec; 16(6):537-40. PubMed ID: 7878690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite.
    Riva R; Contin M; Albani F; Perucca E; Ambrosetto G; Procaccianti G; Santucci M; Baruzzi A
    Ther Drug Monit; 1985; 7(3):277-82. PubMed ID: 4049464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primidone-carbamazepine interaction: clinical consequences.
    Benetello P; Furlanut M
    Int J Clin Pharmacol Res; 1987; 7(2):165-8. PubMed ID: 3583497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence.
    Korinthenberg R; Haug C; Hannak D
    Neuropediatrics; 1994 Aug; 25(4):214-6. PubMed ID: 7824094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 24 hour variation of salivary carbamazepine and carbamazepine-10,11-epoxide concentrations in children with epilepsy.
    Bäckman E; Dahlström G; Eeg-Olofsson O; Bertler A
    Pediatr Neurol; 1987; 3(6):327-30. PubMed ID: 3149473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy.
    Camfield P; Hwang P; Camfield C; Fraser A; Soldin S; al-Quadah AK
    Can J Neurol Sci; 1992 May; 19(2):204-7. PubMed ID: 1623447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism.
    Tomson T; Svensson JO; Hilton-Brown P
    Ther Drug Monit; 1989 Sep; 11(5):533-9. PubMed ID: 2815227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication.
    Zielinski JJ; Haidukewych D; Leheta BJ
    Ther Drug Monit; 1985; 7(1):51-3. PubMed ID: 3992622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing serum levels of carbamazepine and carbamazepine-10,11-epoxide in children.
    Altafullah I; Talwar D; Loewenson R; Olson K; Lockman LA
    Epilepsy Res; 1989; 4(1):72-80. PubMed ID: 2753022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide.
    So EL; Ruggles KH; Cascino GD; Ahmann PA; Weatherford KW
    Ann Neurol; 1994 Jun; 35(6):743-6. PubMed ID: 8210232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice.
    Bourgeois BF; Wad N
    J Pharmacol Exp Ther; 1984 Nov; 231(2):411-5. PubMed ID: 6491988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine.
    Spina E; Tomson T; Svensson JO; Faigle JW; Bertilsson L
    Ther Drug Monit; 1988; 10(4):382-5. PubMed ID: 3201523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laser evoked potentials and carbamazepine in epileptic patients.
    Galeotti F; Truini A; Iannetti GD; Romaniello A; Biasiotta A; Mascia A; Virtuoso M; Cruccu G
    Neurophysiol Clin; 2005 Jul; 35(2-3):93-6. PubMed ID: 16087072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized, double-blind, placebo-controlled trial.
    Gupta M; Gupta YK; Agarwal S; Aneja S; Kalaivani M; Kohli K
    Epilepsia; 2004 Dec; 45(12):1636-9. PubMed ID: 15571523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of drug levels & pharmacokinetics of carbamazepine with seizure control.
    Vasudev A; Tripathi KD; Puri V
    Indian J Med Res; 2000 Dec; 112():218-23. PubMed ID: 11247200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy.
    Chbili C; Hassine A; Ben Amor S; Nouira M; Ben Ammou S; Saguem S
    Rev Neurol (Paris); 2016; 172(4-5):313-7. PubMed ID: 27062293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-drug therapy with carbamazepine in patients with epilepsy: serum levels and clinical effect.
    Strandjord RE; Johannessen SI
    Epilepsia; 1980 Dec; 21(6):655-52. PubMed ID: 6777155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of carbamazepine and carbamazepine-epoxide protein binding in patients undergoing epilepsy surgery.
    Gidal BE; Spencer NW; Maly MM; Pitterle ME
    Epilepsia; 1996 Apr; 37(4):381-5. PubMed ID: 8603645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.
    Brodie MJ; Forrest G; Rapeport WG
    Br J Clin Pharmacol; 1983 Dec; 16(6):747-9. PubMed ID: 6661364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.